Dicerna pharmaceuticals, inc. (DRNA)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Revenue

23,904

6,176

1,030

0

184

-

-

-

Total revenue

-

-

-

-

184

-

-

7,015

Operating expenses:
Research and development

109,339

45,700

35,900

41,399

43,971

29,453

11,558

11,565

General and administrative

42,751

21,685

16,838

15,433

19,240

15,648

5,820

4,700

Litigation expense

0

29,132

9,000

2,916

-

-

-

-

Total operating expenses

152,090

96,528

61,769

59,748

63,211

45,101

17,378

16,265

Loss from operations

-128,186

-90,352

-60,739

-59,748

-63,027

-45,101

-17,378

-9,250

Other income (expense):
Preferred stock warrant liability re-measurement

-

-

-

-

-

2,559

-126

469

Loss on extinguishment of debt

-

-

-

-

-

-143

-318

-

Interest income

7,537

2,102

539

235

188

63

4

2

Interest expense

3

600

0

0

-

199

952

1,342

Other income (expense)

193

0

0

-

-

-

-

-

Total other income, net

7,727

1,499

539

235

-

-2,838

-1,140

-871

Net loss

-120,459

-88,853

-60,200

-59,513

-62,839

-47,939

-18,518

-10,121

Redeemable Preferred Stock Dividends

0

0

10,111

0

-

-

-

-

Preferred Stock Conversions, Inducements

0

0

6,144

0

-

-

-

-

Deemed dividend on conversion of redeemable convertible preferred stock

0

0

-3,837

0

-

-

-

-

Less: accretion and dividends on redeemable convertible preferred stock

-

-

-

-

-

204

2,388

4,097

Net Income (Loss) Available to Common Stockholders, Basic

-120,459

-88,853

-80,292

-59,513

-62,839

-48,143

-20,906

-14,218

Net loss per share – basic and diluted (in dollars per share)

-1.76

-1.60

-3.66

-2.87

-3.09

-3.00

-709.57

-516.00

Weighted average common shares outstanding – basic and diluted (in shares)

68,428

55,616

21,917

20,719

20,320

16,070

29

27